News
Public · Published
Citigroup maintains Krystal Biotech at Buy, lowers price target to $412 from $416
Citigroup kept its Buy rating on Krystal Biotech but lowered its price target to $412 from $416, a 1.0% decrease. That target implies 39.2% upside from the November 2 close of $295.90.
Published:
Updated:
What happened
Citigroup kept its Buy rating on Krystal Biotech but lowered its price target to $412 from $416, a 1.0% decrease. That target implies 39.2% upside from the November 2 close of $295.90.
Confirmed
Global impact / market context
A small cut to a Buy price target still signals Citigroup expects the stock to rise well above its last close. Investors watching analyst targets may treat the trim as a minor adjustment rather than a change in view on the company.
Analyst inference
Other recent analyst notes set targets between $361 and $380, all above the $295.90 close. Citigroup's $412 target is the highest of these, which suggests its analysts see more room for gains than peers covering the same stock.
Analyst inference
What to watch
- Citigroup's $412 target implies 39.2% upside from the November 2 close of $295.90, so watch whether the stock moves toward that level over time. Confirmed
- Watch whether other analysts change their Krystal Biotech price targets, since the three recent notes ranged from $361 to $380 and a shift could show changing views. Proposed
- Watch the company's upcoming results and any pipeline news, because analyst targets rest on future revenue and profit expectations that new data could raise or lower. Analyst inference
Evidence
- Original source link unavailable